MCID: FNC002
MIFTS: 39

Functional Diarrhea

Categories: Gastrointestinal diseases

Aliases & Classifications for Functional Diarrhea

MalaCards integrated aliases for Functional Diarrhea:

Name: Functional Diarrhea 12 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:11371
ICD10 33 K59.1
ICD9CM 35 564.5
SNOMED-CT 64 47812002
UMLS 69 C0156173

Summaries for Functional Diarrhea

MalaCards based summary : Functional Diarrhea is related to hyperimmunoglobulin syndrome and semantic agnosia, and has symptoms including constipation, diarrhea and vomiting following gastrointestinal surgery. An important gene associated with Functional Diarrhea is ITM2B (Integral Membrane Protein 2B), and among its related pathways/superpathways are Serotonergic synapse and Farnesoid X Receptor Pathway. The drugs Aspirin and Ticlopidine have been mentioned in the context of this disorder. Affiliated tissues include colon, heart and liver, and related phenotypes are behavior/neurological and growth/size/body region

Related Diseases for Functional Diarrhea

Diseases related to Functional Diarrhea via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 45)
id Related Disease Score Top Affiliating Genes
1 hyperimmunoglobulin syndrome 10.4 HTR3A HTR7 TAC1
2 semantic agnosia 10.3 HTR7 NTS TAC1
3 cervical adenosarcoma 10.3 HTR7 NTS TAC1
4 retinal hemangioblastoma 10.3 DNTT TAC1
5 scrotum melanoma 10.2 ATP12A ATP4A
6 congenital aphakia 10.2 ATP12A ATP4A
7 shwartzman phenomenon 10.1 ATP12A ATP4A
8 primary syphilis 10.1 ATP12A ATP4A
9 pervasive developmental disorder 10.1 GHRL HTR7 TAC1
10 bone giant cell sarcoma 10.1 ATP12A ATP4A
11 nutritional optic neuropathy 10.1 GHRL HTR4
12 urethral calculus 10.1 ATP12A ATP4A
13 breast ductal adenoma 10.1 ATP12A ATP4A
14 hypopituitarism 10.1 ATP12A ATP4A
15 amyotrophic lateral sclerosis type 5 10.1 ATP12A ATP4A
16 diarrhea 10.0
17 atheroembolism of kidney 10.0 ATP12A ATP4A
18 microphthalmia, syndromic 12 10.0 ATP12A ATP4A
19 synostosis 10.0 ATP12A ATP4A
20 muscle cancer 10.0 ATP12A ATP4A
21 anterior cerebral artery infarction 10.0 ATP12A ATP4A MRPS22
22 adult xanthogranuloma 10.0 ATP12A ATP4A
23 sweat gland cancer 10.0 HTR3A HTR4 TAC1
24 intracranial sinus thrombosis 9.9 ATP12A ATP4A HTR3A
25 polysyndactyly with cardiac malformation 9.9 ATP12A ATP4A
26 cloacal exstrophy 9.9 ATP12A ATP4A
27 thrombocytopenia due to platelet alloimmunization 9.8 ATP12A ATP4A
28 irritable bowel syndrome 9.8
29 proliferative fasciitis 9.8 ATP12A ATP4A
30 spinocerebellar ataxia 18 9.8 ATP12A ATP4A
31 endometrial clear cell adenocarcinoma 9.8 GHRL HTR4 TAC1
32 focal hand dystonia 9.8 ATP12A ATP4A TAC1
33 myositis fibrosa 9.8 HTR3A HTR4 HTR7 TAC1
34 abnormal pupillary function 9.7 ATP12A ATP4A HTR3A HTR7
35 hodgkin's paragranuloma 9.7 ATP12A ATP4A
36 farber lipogranulomatosis 9.6 ATP12A ATP4A RAB11A
37 bladder neck cancer 9.5 ATP12A ATP4A
38 constipation 9.5
39 dyspepsia 9.5
40 cerebritis 9.5
41 allergic urticaria 9.4 ATP12A ATP4A GHRL TAC1
42 scleral staphyloma 9.4 ATP12A ATP4A GHRL HTR3A HTR7
43 fibrosarcomatous osteosarcoma 9.2 ATP12A ATP4A GHRL HTR4
44 tuberculum sellae meningioma 9.2 ATP12A ATP4A GHRL HTR4
45 gnathomiasis 4.2 ATP12A ATP4A CDH1 CDK5RAP2 DNTT FGF19

Comorbidity relations with Functional Diarrhea via Phenotypic Disease Network (PDN):


Acute Cystitis Heart Disease

Graphical network of the top 20 diseases related to Functional Diarrhea:



Diseases related to Functional Diarrhea

Symptoms & Phenotypes for Functional Diarrhea

UMLS symptoms related to Functional Diarrhea:


constipation, diarrhea, vomiting following gastrointestinal surgery

MGI Mouse Phenotypes related to Functional Diarrhea:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.96 TAC1 TOR1A GHRL HTR3A HTR4 HTR7
2 growth/size/body region MP:0005378 9.93 ATP12A CDH1 CDK5RAP2 FGF19 GPBAR1 HTR3A
3 homeostasis/metabolism MP:0005376 9.83 PIK3C2A TOR1A ATP12A ATP4A CDH1 DNTT
4 adipose tissue MP:0005375 9.8 GHRL GPBAR1 HTR4 NR1H4 NTS PIK3C2A
5 immune system MP:0005387 9.32 ATP4A CDH1 CDK5RAP2 DNTT GPBAR1 HTR3A

Drugs & Therapeutics for Functional Diarrhea

Drugs for Functional Diarrhea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 418)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Ticlopidine Approved Phase 4 55142-85-3 5472
3
Loperamide Approved Phase 4,Phase 2,Phase 3,Phase 1 53179-11-6 3955
4
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
5
Budesonide Approved Phase 4,Phase 3 51333-22-3 63006 5281004
6 lanreotide Approved Phase 4 108736-35-2
7
Somatostatin Approved Phase 4 38916-34-6, 51110-01-1 53481605
8
rituximab Approved Phase 4 174722-31-7 10201696
9
Donepezil Approved Phase 4 120014-06-4 3152
10
Dopamine Approved Phase 4,Phase 1 51-61-6, 62-31-7 681
11
Galantamine Approved Phase 4 357-70-0 9651
12
Memantine Approved, Investigational Phase 4 19982-08-2 4054
13
Rivastigmine Approved, Investigational Phase 4,Phase 1 123441-03-2 77991
14
Paroxetine Approved, Investigational Phase 4,Phase 2 61869-08-7 43815
15
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
16 Ramosetron Approved Phase 4,Phase 3,Phase 2 132036-88-5
17
Zinc Approved Phase 4,Phase 3,Phase 2 7440-66-6 32051 23994
18
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
19
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2 80621-81-4 6436173
20
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
21
Mycophenolic acid Approved Phase 4 24280-93-1 446541
22
Acetylcholine Approved Phase 4 51-84-3 187
23
Eluxadoline Approved Phase 4 864821-90-9
24
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
25
Clopidogrel Approved, Nutraceutical Phase 4 120202-66-6, 113665-84-2 60606
26
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
27
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 1406-16-2
28
Choline Approved, Nutraceutical Phase 4 62-49-7 305
29
Genistein Investigational Phase 4 446-72-0 5280961
30 Antihypertensive Agents Phase 4,Phase 3
31 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Cholinergic Agents Phase 4,Phase 1,Early Phase 1
33 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Sulfalene Phase 4,Phase 3,Phase 1,Phase 2
35 Hormone Antagonists Phase 4,Phase 3,Phase 2
36 Hormones Phase 4,Phase 3,Phase 2
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
38 Imatinib Mesylate Phase 4 123596
39 Antibodies Phase 4,Phase 2
40 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Immunoglobulins Phase 4,Phase 2
42 Excitatory Amino Acid Antagonists Phase 4
43 Excitatory Amino Acids Phase 4
44 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
45
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
46 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Bronchodilator Agents Phase 4,Phase 3,Phase 1
50 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 293)

id Name Status NCT ID Phase Drugs
1 Saccharomyces Boulardii in Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
2 Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS Study) Unknown status NCT01208714 Phase 4 Optimal medical therapy
3 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
4 Probiotic in Irritable Bowel Syndrome (IBS) Patients With Diarrhea Unknown status NCT01667627 Phase 4
5 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
6 Mode of Action of Moviprep Completed NCT01622972 Phase 4 Polyethyleneglycol
7 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients Completed NCT02075606 Phase 4 lanreotide acetate
8 Study of Rituximab to Treat Chronic Renal Transplant Rejection Completed NCT00476164 Phase 4 Rituximab
9 Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment Completed NCT00234637 Phase 4 Rivastigmine, memantine
10 Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
11 A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT02275052 Phase 4 UMEC/VI DPI;Placebo DPI;Albuterol/salbutamol MDI
12 Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D) Completed NCT01316718 Phase 4 Mesalazine;Placebo
13 Study to Assess the Effect Of Alosetron On Mucosal Blood Flow Completed NCT00370032 Phase 4 alosetron
14 Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D) Completed NCT00745004 Phase 4 Ondansetron;Placebo
15 A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients Completed NCT01225237 Phase 4 Ramosetron;Placebo
16 A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT00918411 Phase 4 Ramosetron;Placebo
17 Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS Completed NCT00142987 Phase 4 Tegaserod
18 Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids Completed NCT02111603 Phase 4 Colesevelam
19 Airway Hyper-responsiveness Study In Asthma Using Salmeterol/Fluticasone Propionate Combination Product Completed NCT00291382 Phase 4 Salmeterol/fluticasone propionate combination
20 Optimal Amount of Zinc to Include in a Lipid-based Nutrient Supplement (LNS) Completed NCT00944281 Phase 4
21 Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome Completed NCT02026518 Phase 4
22 Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic-associated Diarrhea in Children Recruiting NCT02765217 Phase 4 Lactobacillus reuteri DSM 17938;Placebo;Amoxicillin-Clavulanic Acid
23 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders Recruiting NCT01098383 Phase 4 Acetyl-Choline Esterase Inhibitors and Choline supplements;Indistinguishable placebo tablets, matching both donepezil and choline
24 Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use Recruiting NCT02959983 Phase 4 Eluxadoline;Placebo
25 A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Recruiting NCT03034915 Phase 4 UMEC/VI 62.5/25 mcg via ELLIPTA;UMEC 62.5 mcg via ELLIPTA;Salmeterol 50 mcg via DISKUS;Placebo via ELLIPTA;Placebo via DISKUS
26 Lactibiane Tolérance® in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance Recruiting NCT02728063 Phase 4
27 A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing Not yet recruiting NCT03219528 Phase 4 Rifaximin 550 MG
28 Neotililty Trial: Effect of Coenzyme Q10 on Semen Parameters in Men With Idiopathic Infertility Not yet recruiting NCT03104998 Phase 4 Coenzyme Q10;Placebo Oral Tablet
29 Probiotics in Newly Recognized Type 1 Diabetes Not yet recruiting NCT03032354 Phase 4 Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12
30 Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation Terminated NCT00656266 Phase 4 MMF (Cellcept);placebo
31 Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma Terminated NCT01070888 Phase 4 Budesonide/Formoterol;Budesonide
32 The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study Terminated NCT00164099 Phase 4 Synbiotic 2000
33 Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse Terminated NCT01092624 Phase 4 Solifenacin;Placebo
34 Enteric Coated Myfortic for Liver Transplant Recipients Withdrawn NCT00167492 Phase 4 Myfortic
35 Effects of Mesalamine and Amitriptyline on Irritable Bowel Syndrome Withdrawn NCT02190526 Phase 4 Mesalazine(asacol 800 mg);Amitriptyline;placebo like asacol;placebo like amitriptyline
36 Imodium Syrup Versus Imodium Tablets for Faecal Incontinence Withdrawn NCT00933465 Phase 4 Imodium (Loperamide Hydrochloride) syrup;Imodium (Loperamide hydrochloride) tablets
37 Multistrain Probiotic for Functional Constipation Unknown status NCT01618617 Phase 2, Phase 3
38 Multicenter Withdrawal Clinical Trials of N-acetyl Glucosamine Capsule for IBS-D Treatment Unknown status NCT01893606 Phase 2, Phase 3 N-acetyl-D-glucosamine;placebo
39 Clinical Trials of N-acetyl Glucosamine Capsule for IBS-D Treatment Unknown status NCT02504060 Phase 3 Starch Placebo;N-acetyl-D-glucosamine
40 Acupuncture for Patients With Diarrhea-predominant IBS or Functional Diarrhea: a Randomized Controlled Trial Completed NCT01350570 Phase 2, Phase 3 Loperamide
41 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3 octreotide acetate
42 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) Completed NCT02107196 Phase 3 Ibodutant 10 mg;Placebo
43 Immunological and Clinical Responses to Zinc in Children With Diarrhoea Completed NCT00408356 Phase 3 Zinc
44 Community Based Prevention of Rotavirus Gastroenteritis by a Functional Food Supplement Completed NCT01265355 Phase 2, Phase 3
45 Randomized, Controlled Trial - Lactoferrin Prevention of Diarrhea in Children Completed NCT00560222 Phase 3
46 Oral Rehydration SolutionContaining Amylase Resistant Starch in Severely Malnourished Children. Completed NCT00324285 Phase 3 Amylase resistant starch added ORS
47 Intervention and Mechanisms of Alanyl-Glutamine for Inflammation, Nutrition, and Enteropathy Completed NCT01832636 Phase 3
48 Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001) Completed NCT01553591 Phase 3 JNJ-27018966;Placebo
49 Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002) Completed NCT01553747 Phase 3 JNJ-27018966
50 Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer Completed NCT00075868 Phase 3 octreotide acetate

Search NIH Clinical Center for Functional Diarrhea

Genetic Tests for Functional Diarrhea

Anatomical Context for Functional Diarrhea

MalaCards organs/tissues related to Functional Diarrhea:

39
Colon, Heart, Liver, Testes, Small Intestine, Endothelial, Bone

Publications for Functional Diarrhea

Articles related to Functional Diarrhea:

(show all 15)
id Title Authors Year
1
Early weaning stress induces chronic functional diarrhea, intestinal barrier defects, and increased mast cell activity in a porcine model of early life adversity. ( 28573751 )
2017
2
Electroacupuncture for patients with diarrhea-predominant irritable bowel syndrome or functional diarrhea: A randomized controlled trial. ( 27310980 )
2016
3
Influence of acupuncture stimulation on cerebral network in functional diarrhea. ( 24459533 )
2013
4
Epidemiology of functional diarrhea and comparison with diarrhea-predominant irritable bowel syndrome: a population-based survey in China. ( 22937091 )
2012
5
Functional diarrhea. ( 22917168 )
2012
6
Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA. ( 17549631 )
2008
7
Treatment of functional diarrhea. ( 16836952 )
2006
8
Functional diarrhea. ( 16168232 )
2005
9
Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. ( 11686387 )
2001
10
Inhibition of gastric secretion relieves diarrhea and postprandial urgency associated with irritable bowel syndrome or functional diarrhea. ( 10505731 )
1999
11
Rapid gastric emptying in patients with functional diarrhea. ( 9121178 )
1997
12
Colonic motility and functional diarrhea. ( 1622483 )
1992
13
Effect of eating on colonic motility and transit in patients with functional diarrhea. Simultaneous scintigraphic and manometric evaluations. ( 1936800 )
1991
14
Functional diarrhea: an analysis of the clinical and roentgen manifestations. ( 13397691 )
1956
15
Alterations in colonic function in man under stress; hypomotility of the sigmoid colon, and its relationship to the mechanism of functional diarrhea. ( 15421433 )
1950

Variations for Functional Diarrhea

Expression for Functional Diarrhea

Search GEO for disease gene expression data for Functional Diarrhea.

Pathways for Functional Diarrhea

Pathways related to Functional Diarrhea according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.18 HTR3A HTR4 HTR7
2 10.54 FGF19 NR1H4
3 10.43 HTR4 HTR7
4 10.25 HTR3A HTR4 HTR7

GO Terms for Functional Diarrhea

Cellular components related to Functional Diarrhea according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.26 GHRL HTR3A RAB11A TAC1
2 transport vesicle GO:0030133 8.8 NTS RAB11A TOR1A

Biological processes related to Functional Diarrhea according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuron projection development GO:0031175 9.5 CDH1 RAB11A TOR1A
2 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.26 ATP12A ATP4A
3 negative regulation of tumor necrosis factor secretion GO:1904468 8.85 NR1H4
4 positive regulation of adipose tissue development GO:1904179 8.65 NR1H4
5 negative regulation of bile acid biosynthetic process GO:0070858 8.62 FGF19 NR1H4

Molecular functions related to Functional Diarrhea according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 serotonin binding GO:0051378 9.26 HTR3A HTR7
2 sodium:potassium-exchanging ATPase activity GO:0005391 9.16 ATP12A ATP4A
3 hydrogen:potassium-exchanging ATPase activity GO:0008900 8.96 ATP12A ATP4A
4 bile acid receptor activity GO:0038181 8.62 GPBAR1 NR1H4

Sources for Functional Diarrhea

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....